The global Microbiome Drugs market size is predicted to grow from US$ 514 million in 2025 to US$ 3235 million in 2031; it is expected to grow at a CAGR of 35.9% from 2025 to 2031.

Microbiome Drug is a kind of medicine made with microorganisms. It is divided into three categories:

• drugs derived from whole or part of microorganisms
• drugs derived from microbial primary metabolites
• drugs derived from microbial secondary metabolites

North America and Europe hold most of market share of microbiome drugs, with North America occupying a share over 77% and Europe taking a share of over 22%. Global core microbiome drugs manufacturers include:

• Seres Therapeutics
• Assembly Biosciences
• Synthetic Biologics

This Insight Report provides a comprehensive analysis of the global Microbiome Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyses the strategies of leading global companies with a focus on Microbiome Drugs portfolios to better understand these firms’ unique position in the market.

Segmentation by Type:

• Oral Dosage Form
• Enteric Capsules

Segmentation by Symptom:

• Gastrointestinal Disorders
• Autoimmune Disorders
• Diabetes
• Cancer
• Others

This report splits the market by region:

• Americas
• APAC
• Europe
• Middle East & Africa

Companies covered:

• Seres Therapeutics
• Assembly Biosciences
• Synthetic Biologics
• Interxon
• PureTech
• Synlogic
• Enterome BioScience
• 4D Pharma
• Second Genome
• AOBiome
• Rebiotix
• Metabiomics
• Ritter Pharmaceuticals
• Symberix
• OpenBiome
• Azitra
• Osel

Key Questions Addressed in this Report: